New eye drug SCT520FF hopes to tackle wet AMD
NCT ID NCT06672536
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests an experimental drug called SCT520FF for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 82 adults aged 45 to 80 will receive either SCT520FF or an existing treatment (EYLEA) via eye injections. Researchers will check safety, side effects, and whether the drug improves vision and reduces retinal swelling.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SCT520FF (an experimental drug injected into the eye)
- What this could lead to
- If successful, this could offer a new treatment option for wet AMD, potentially improving vision and reducing the need for frequent eye injections.
- What could go wrong
- This is an early-phase trial with only 82 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve vision better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAMD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Eye Hospital
RECRUITINGTianjing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- New eye drug aims to offer cheaper option for blinding disease
- Gene therapy could end frequent eye injections for wet AMD
- One-Shot gene therapy could end monthly eye injections for wet AMD
- Eye implant could replace monthly shots for blinding disease